On April 4, 2024, Invivyd, Inc., a biopharmaceutical company, announced the commercial availability of PEMGARDA™ in the United States for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise. The announcement follows the emergency use authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) on March 22, 2024. Invivyd also provided net product revenue guidance for 2024, projecting $150 million to $200 million, and expects to end the year with at least $55 million in cash and cash equivalents. A conference call was scheduled for the same day to discuss the launch progress of PEMGARDA. Additionally, Invivyd updated its corporate presentation on its website and filed it as Exhibit 99.2. PEMGARDA, which targets the SARS-CoV-2 spike protein, is available by prescription through a network of authorized specialty distributors. Invivyd's proprietary INVYMAB™ platform combines viral surveillance and predictive modeling with advanced antibody engineering to rapidly generate new monoclonal antibodies to combat evolving viral threats.

On April 4, 2024, Invivyd, Inc., a biopharmaceutical company, announced the commercial availability of PEMGARDA™ in the United States for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise. The announcement follows the emergency use authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) on March 22, 2024. Invivyd also provided net product revenue guidance for 2024, projecting $150 million to $200 million, and expects to end the year with at least $55 million in cash and cash equivalents. A conference call was scheduled for the same day to discuss the launch progress of PEMGARDA. Additionally, Invivyd updated its corporate presentation on its website and filed it as Exhibit 99.2. PEMGARDA, which targets the SARS-CoV-2 spike protein, is available by prescription through a network of authorized specialty distributors. Invivyd's proprietary INVYMAB™ platform combines viral surveillance and predictive modeling with advanced antibody engineering to rapidly generate new monoclonal antibodies to combat evolving viral threats.